TipRanks
Advertisement
Advertisement
Rani Therapeutics reports initial data from RT-114 study
PremiumThe FlyRani Therapeutics reports initial data from RT-114 study
3M ago
Rani Therapeutics Maintained at Buy as Partnerships Highlight Underappreciated Pipeline; $11 Price Target Reaffirmed
Premium
Ratings
Rani Therapeutics Maintained at Buy as Partnerships Highlight Underappreciated Pipeline; $11 Price Target Reaffirmed
3M ago
Rani Therapeutics announces research, development collaboration with PegBio
Premium
The Fly
Rani Therapeutics announces research, development collaboration with PegBio
3M ago
Rani Therapeutics Shareholders Back Board and Auditor at Meeting
PremiumCompany AnnouncementsRani Therapeutics Shareholders Back Board and Auditor at Meeting
5M ago
Rani Therapeutics Announces $20 Million Equity Financing
Premium
Company Announcements
Rani Therapeutics Announces $20 Million Equity Financing
5M ago
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price
Premium
Company Announcements
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price
5M ago
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
PremiumThe FlyRani Therapeutics price target lowered to $5 from $9 at Canaccord
7M ago
Rani Therapeutics reports Q4 EPS (7c), consensus (7c)
Premium
The Fly
Rani Therapeutics reports Q4 EPS (7c), consensus (7c)
7M ago
Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings
Premium
The Fly
Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings
7M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―